



sample	cell type	mixed	classified
a	WBC	60%	61.6%
	MCF7	20%	22.3%
	HL60	20%	16.1%
b	WBC	60%	58.3%
	MCF7	40%	37.0%
	HL60	0%	4.7%
c	WBC	80%	76.7%
	MCF7	0%	2.3%
	HL60	20%	21.0%

Figure 5. (a) Density profiles of Jurkat cells after 1–3 days of treatment with TSA (1, 2 μ M) show that at higher dosages and treatment times, a portion of the population becomes stiff and small. (b) The profile of spiked and pure samples of live and fixed Jurkat cells. (c) Data shows high correlation between predicted viability and viability calculated using a standard cytotoxicity assay. (d) 2D profiles for healthy leukocytes (WBC), MCF7, and HL60 cells. (e) Three-dimensional profiles of diameter (A), deformability (D3), and deformation rate (T2) for three differently mixed samples of WBCs (cyan), HL60s (red), and MCF7s (blue). Classification using all 15 parameters led to < 5% error in classification of three differently mixed samples.